<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7135364/results/search/disease/results.xml">
  <result pre=": Article Arguments in favour of remdesivir for treating SARS-CoV-2" exact="infections" post="KoWen-ChienabRolainJean-MarccdLeeNan-YaoabChenPo-LinabHuangChing-TaieLeePing-IngfHsuehPo-Renhsporen@ntu.edu.twgh⁎[a], [b], [c], [d], [e], [f], [g], [h], ⁎Corresponding"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="the COVID-19 resource centre remains active. Keywords Remdesivir Betacoronavirus SARS-CoV-2" exact="Coronavirus disease" post="2019 COVID-19 Wuhan pneumonia 1 Introduction Since the end"/>
  <result pre="COVID-19 resource centre remains active. Keywords Remdesivir Betacoronavirus SARS-CoV-2 Coronavirus" exact="disease" post="2019 COVID-19 Wuhan pneumonia 1 Introduction Since the end"/>
  <result pre="active. Keywords Remdesivir Betacoronavirus SARS-CoV-2 Coronavirus disease 2019 COVID-19 Wuhan" exact="pneumonia" post="1 Introduction Since the end of 2019, an increasing"/>
  <result pre="the end of 2019, an increasing number of cases of" exact="pneumonia" post="were reported in Wuhan, followed by other cities and"/>
  <result pre="[6], [7], and the 2019 novel coronavirus (2019-nCoV) or severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [8], a new human"/>
  <result pre="[7], and the 2019 novel coronavirus (2019-nCoV) or severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [8], a new human pathogen,"/>
  <result pre="and the 2019 novel coronavirus (2019-nCoV) or severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [8], a new human pathogen, was"/>
  <result pre="pathogen, was identified as the cause of Wuhan pneumonia. The" exact="disease" post="spectrum of SARS-CoV-2 infection, so-called coronavirus disease 2019 (COVID-19),"/>
  <result pre="of Wuhan pneumonia. The disease spectrum of SARS-CoV-2 infection, so-called" exact="coronavirus disease" post="2019 (COVID-19), was known to be diverse in severity,"/>
  <result pre="Wuhan pneumonia. The disease spectrum of SARS-CoV-2 infection, so-called coronavirus" exact="disease" post="2019 (COVID-19), was known to be diverse in severity,"/>
  <result pre="be diverse in severity, ranging from asymptomatic carriage to mild" exact="respiratory" post="tract infection and severe or fatal pneumonia. Moreover, SARS-CoV-2"/>
  <result pre="in severity, ranging from asymptomatic carriage to mild respiratory tract" exact="infection" post="and severe or fatal pneumonia. Moreover, SARS-CoV-2 can be"/>
  <result pre="Before the current COVID-19 epidemic, there were six recognised human" exact="respiratory" post="coronaviruses, including HCoV-229E (Alphacoronavirus), HCoV-OC43 (Betacoronavirus), HCoV-NL63 (Alphacoronavirus) and"/>
  <result pre="(Betacoronavirus), HCoV-NL63 (Alphacoronavirus) and HKU1 (Betacoronavirus) that often cause mild" exact="respiratory" post="tract infection as well as SARS-CoV and MERS-CoV that"/>
  <result pre="(Alphacoronavirus) and HKU1 (Betacoronavirus) that often cause mild respiratory tract" exact="infection" post="as well as SARS-CoV and MERS-CoV that in contrast"/>
  <result pre="that in contrast can lead to severe or even fatal" exact="lower" post="respiratory tract disease [9]. The seventh human coronavirus, SARS-CoV-2,"/>
  <result pre="in contrast can lead to severe or even fatal lower" exact="respiratory" post="tract disease [9]. The seventh human coronavirus, SARS-CoV-2, belongs"/>
  <result pre="can lead to severe or even fatal lower respiratory tract" exact="disease" post="[9]. The seventh human coronavirus, SARS-CoV-2, belongs to the"/>
  <result pre="monoclonal antibodies or vaccines have been approved to treat human" exact="infections" post="due to coronaviruses. Several pre-existing and potential drug candidates,"/>
  <result pre="polymerase (RdRp) shares 96% sequence identity [11]. Therefore, drugs targeting" exact="viral" post="RdRp proteins of SARS-CoV are likely to be effective"/>
  <result pre="a nucleotide analogue of adenosine 5-monophosphate with antiviral activity against" exact="hepatitis" post="B virus and human immunodeficiency virus (HIV). It was"/>
  <result pre="5-monophosphate with antiviral activity against hepatitis B virus and human" exact="immunodeficiency" post="virus (HIV). It was developed by Gilead Science Inc."/>
  <result pre="has been recommended for the treatment of cats with feline" exact="infectious" post="peritonitis, which is uncommon but fatal and is caused"/>
  <result pre="triphosphate works as an incorporation competitor with adenosine triphosphate, confuses" exact="viral" post="RdRp, acts as a delayed RNA chain terminator against"/>
  <result pre="RNA chain terminator against Ebola virus [15,16], evades proofreading by" exact="viral" post="exoribonuclease, and causes a decrease in viral RNA production"/>
  <result pre="evades proofreading by viral exoribonuclease, and causes a decrease in" exact="viral" post="RNA production [17]. Recently, the antiviral activity of remdesivir"/>
  <result pre="active against Ebola virus in multiple human cell types, including" exact="primary" post="macrophages and human endothelial cells, with low half-maximal effective"/>
  <result pre="in vitro against Marburg virus [15], Paramyxoviridae (such as parainfluenza" exact="type 3" post="virus, Nipah virus, Hendra virus, and measles and mumps"/>
  <result pre="as parainfluenza type 3 virus, Nipah virus, Hendra virus, and" exact="measles" post="and mumps viruses) and Pneumoviridae (such as respiratory syncytial"/>
  <result pre="type 3 virus, Nipah virus, Hendra virus, and measles and" exact="mumps" post="viruses) and Pneumoviridae (such as respiratory syncytial virus) [19]."/>
  <result pre="virus, and measles and mumps viruses) and Pneumoviridae (such as" exact="respiratory" post="syncytial virus) [19]. In primary human airway epithelial cell"/>
  <result pre="viruses) and Pneumoviridae (such as respiratory syncytial virus) [19]. In" exact="primary" post="human airway epithelial cell culture, a biologically relevant in"/>
  <result pre="(such as respiratory syncytial virus) [19]. In primary human airway" exact="epithelial" post="cell culture, a biologically relevant in vitro model of"/>
  <result pre="epithelial cell culture, a biologically relevant in vitro model of" exact="pulmonary" post="infection, remdesivir was shown to inhibit SARS-CoV [half-maximal inhibitory"/>
  <result pre="many human and zoonotic coronaviruses, including HCoV-NL63, HCoV-OC43, HCoV-229E, mouse" exact="hepatitis" post="virus (MHV) (Betacoronavirus), SARS-CoV and related bat coronaviruses WIV1"/>
  <result pre="and V553L mutations was outcompeted by wild-type MHV in the" exact="absence of" post="GS-5734, suggestive of the effect of remdesivir resistance on"/>
  <result pre="GS-5734, suggestive of the effect of remdesivir resistance on decreased" exact="viral" post="fitness. Of note, in the mouse model of SARS-CoV"/>
  <result pre="lost less weight and had a more evident decline in" exact="pulmonary" post="viral loads by 4 days after infection than wild-type"/>
  <result pre="less weight and had a more evident decline in pulmonary" exact="viral" post="loads by 4 days after infection than wild-type SARS-CoV-infected"/>
  <result pre="evident decline in pulmonary viral loads by 4 days after" exact="infection" post="than wild-type SARS-CoV-infected mice, indicative of attenuated pathogenicity of"/>
  <result pre="it has been further tested in animal models of different" exact="viral" post="infections. In a rhesus monkey model of Ebola virus"/>
  <result pre="Ebola virus and protected all infected animals against this lethal" exact="infection" post="[15]. Besides, in a mouse model of SARS-CoV infection,"/>
  <result pre="prophylactic and early therapeutic dosing of remdesivir effectively decreased the" exact="viral" post="load in the lungs and improved pulmonary function [20]."/>
  <result pre="effectively decreased the viral load in the lungs and improved" exact="pulmonary" post="function [20]. According to the previous rhesus monkey model"/>
  <result pre="[20]. According to the previous rhesus monkey model of Ebola" exact="virus infection," post="an intravenous (i.v.) 10 mg/kg dose of remdesivir could"/>
  <result pre="lead to a lasting level of active triphosphate form in" exact="peripheral" post="blood mononuclear cells (PBMCs), &amp;gt;10 μM, for at least"/>
  <result pre="in the animal study the plasma half-life of remdesivir was" exact="short" post="(0.39 h), remdesivir was rapidly distributed into PBMCs, converted"/>
  <result pre="and had an intracellular half-life of 14 h. In the" exact="absence of" post="any human pharmacokinetic information, such data from rhesus monkeys"/>
  <result pre="preliminary evidence supporting the clinical potential of remdesivir for human" exact="infections" post="caused by contemporary and emerging coronaviruses, including SARS-CoV-2. Early"/>
  <result pre="including SARS-CoV-2. Early clinical experience of remdesivir therapy in a" exact="female" post="nurse from Scotland with Ebola meningoencephalitis, which was supported"/>
  <result pre="in plasma and cerebrospinal fluid, its first use for Ebola" exact="virus infection" post="in humans, was reported in 2016 [22]. She was"/>
  <result pre="plasma and cerebrospinal fluid, its first use for Ebola virus" exact="infection" post="in humans, was reported in 2016 [22]. She was"/>
  <result pre="days). No serious clinical or biochemical events occurred except a" exact="transient" post="rise of serum amylase level. In a recently published,"/>
  <result pre="trial of four experimental therapeutics for Ebola virus disease, a" exact="total" post="of 175 patients ever received remdesivir [23]. Although remdesivir"/>
  <result pre="not challenged. One patient on remdesivir therapy developed hypotension and" exact="cardiac arrest" post="after discontinuation of the loading dose; however, the authors"/>
  <result pre="be related to underlying Ebola virus disease, a potentially fatal" exact="infectious disease." post="5 Preliminary data on the clinical efficacy of remdesivir"/>
  <result pre="Preliminary data on the clinical efficacy of remdesivir in COVID-19" exact="pneumonia" post="and ongoing clinical trials The first case of COVID-19"/>
  <result pre="was compassionately treated with i.v. remdesivir for the progression of" exact="pneumonia" post="on Day 7 of hospitalisation [24]. Interestingly, the patient's"/>
  <result pre="but the authors noted a trend in the decline of" exact="viral" post="load in nasopharyngeal swabs [cycle threshold values: illness Day"/>
  <result pre="the direct antiviral effect of remdesivir on enhanced clearing of" exact="viral" post="loads in the respiratory tract, but it indeed suggests"/>
  <result pre="of remdesivir on enhanced clearing of viral loads in the" exact="respiratory" post="tract, but it indeed suggests a promising therapeutic effect"/>
  <result pre="was used in the randomised clinical trial of Ebola virus" exact="disease" post="[23]. 6 Conclusions With an effective reduction of pulmonary"/>
  <result pre="virus disease [23]. 6 Conclusions With an effective reduction of" exact="pulmonary" post="viral load in a murine model of SARS-CoV infection,"/>
  <result pre="disease [23]. 6 Conclusions With an effective reduction of pulmonary" exact="viral" post="load in a murine model of SARS-CoV infection, potent"/>
  <result pre="the window for effective antiviral therapy for such an epidemic" exact="infectious disease." post="References References 1ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with pneumonia"/>
  <result pre="infectious disease. References References 1ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med382202072773310.1056/NEJMoa200101731978945 2LiQ.GuanX.WuP.WangX.ZhouL.TongY.Early transmission dynamics"/>
  <result pre="pneumoniaN Engl J Med2020 Jan 2910.1056/NEJMoa2001316[Epub ahead of print] 3ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="Med2020 Jan 2910.1056/NEJMoa2001316[Epub ahead of print] 3ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="5ChenN.ZhouM.DongX.QuJ.GongF.HanY.Epidemiological and clinical characteristics of 99 cases of 2019 novel" exact="coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 6LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute respiratory"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 6LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute respiratory"/>
  <result pre="novel coronavirus pneumonia in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 6LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
  <result pre="coronavirus pneumonia in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 6LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
  <result pre="pneumonia in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 6LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
  <result pre="R.S., de Groot R.J., Drosten C., Gulyaeva A.A., et al." exact="Severe" post="acute respiratory syndrome-related coronavirus: the species and its viruses—a"/>
  <result pre="de Groot R.J., Drosten C., Gulyaeva A.A., et al. Severe" exact="acute" post="respiratory syndrome-related coronavirus: the species and its viruses—a statement"/>
  <result pre="Groot R.J., Drosten C., Gulyaeva A.A., et al. Severe acute" exact="respiratory" post="syndrome-related coronavirus: the species and its viruses—a statement of"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChembiochem21202073073810.1002/cbic.20200004732022370 12LiG.CleraqE.D.Therapeutic options for the"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChembiochem21202073073810.1002/cbic.20200004732022370 12LiG.CleraqE.D.Therapeutic options for the 2019"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChembiochem21202073073810.1002/cbic.20200004732022370 12LiG.CleraqE.D.Therapeutic options for the 2019 novel"/>
  <result pre="analog GS-441524 for treatment of cats with naturally occurring feline" exact="infectious" post="peritonitisJ Feline Med Surg21201927128110.1177/1098612X1982570130755068 15WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.Therapeutic efficacy of the small"/>
  <result pre="of Ebola virus RNA-dependent RNA polymerase by remdesivirViruses11201910.3390/v11040326pii: E326 17AgostiniM.L.AndresE.SimsA.C.GrahamR.L.SheahanT.P.LuX.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 18WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine"/>
  <result pre="case reportLancet338201649850310.1016/S0140-6736(16)30386-5 23MulanguS.DoddL.E.DaveyR.T.JrTshiani MbayaO.ProschanM.MukadiD.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med38120192293230310.1056/NEJMoa191099331774950 24HolshueM.L.DeBoltC.LindquistS.LofyK.H.WiesmanJ.BruceH.First case of 2019 novel"/>
 </snippets>
</snippetsTree>
